Ioxilan
From Wikipedia, the free encyclopedia
 |
|
|
Ioxilan
|
|
| Systematic (IUPAC) name | |
| 5-(acetyl-(2,3-dihydroxypropyl)amino)-N'-(2,3-dihydroxypropyl)-N-(2-hydroxy ethyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C18H24I3N3O8 |
| Mol. mass | 791.112 |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | negligible |
| Metabolism | ? |
| Half life | 2 hours |
| Excretion | Mostly renal |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | intravenously |
Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
